Effect of Saxagliptin Treatment on Myocardial Fat Content, Left Ventricular Function, and Monocyte Inflammation in Patients With Impaired Glucose Tolerance.
Phase of Trial: Phase IV
Latest Information Update: 07 Jun 2017
At a glance
- Drugs Saxagliptin (Primary)
- Indications Diabetes mellitus; Glucose intolerance
- Focus Biomarker; Pharmacodynamics
- 07 Jun 2017 Biomarkers information updated
- 31 May 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
- 31 May 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.